Skip to main navigation Skip to main content

CMH : Clinical and Molecular Hepatology

OPEN ACCESS
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Page Path

7
results for

"Woo Kyu Jeon"

Article category

Keywords

Publication year

"Woo Kyu Jeon"

Case Report

Hepatic neoplasm

Complete cure of advanced hepatocellular carcinoma with right adrenal gland metastasis and portal vein thrombosis by multiple applications of an interdisciplinary therapy: case report with 8-year follow up
Hojung Jung, Byung Ik Kim, Yong Kyun Cho, Woo Kyu Jeon, Hong Joo Kim, Hyun Pyo Hong
Clin Mol Hepatol 2018;24(4):424-429.
Published online November 14, 2017
DOI: https://doi.org/10.3350/cmh.2017.0032
Hepatocellular carcinoma (HCC) is the sixth most common cause of death worldwide and the main cause of primary liver cancer. The principle problem of HCC is the poor prognosis, since advanced HCC reportedly has a median survival of only 9 months. The standard therapies are sorafenib and regorafenib, but the outcomes remain unclear. We report a 60-year-old man with advanced HCC with right adrenal gland metastasis and portal vein tumor thrombosis, who showed a complete response to multiple applications of an interdisciplinary therapy.

Citations

Citations to this article as recorded by  Crossref logo
  • Long-term sustained complete response with off-therapy to sorafenib in advanced hepatocellular carcinoma: a case report
    Takeshi Koujima, Yoshikatsu Endo, Takeharu Yamamoto, Toshifumi Tada, Kazuhiko Morii, Shinichiro Nakamura, Kyohei Kai
    Kanzo.2020; 61(5): 255.     CrossRef
  • 14,437 View
  • 183 Download
  • 1 Web of Science
  • Crossref
Original Articles

Viral hepatitis

Clinical characteristics of patients with chronic hepatitis B who developed genotypic resistance to entecavir: Real-life experience
Hong Joo Kim, Yong Kyun Cho, Woo Kyu Jeon, Byung Ik Kim
Clin Mol Hepatol 2017;23(4):323-330.
Published online September 5, 2017
DOI: https://doi.org/10.3350/cmh.2017.0005
Background/Aims
Clinical characteristics of patients with chronic hepatitis B (CHB) who developed genotypic resistance to entecavir (ETV) were compared to those without resistance.
Methods
Two hundred fifty eight CHB patients who underwent ETV treatment in our institution from July 2007 to May 2013 were included.
Results
Eight (3.1%) patients developed genotypic resistance to ETV during the follow-up period. The patterns of genotypic resistance to ETV were as follows: L180M + M204V + S202G (n=3); M204I + V173M (n=1); I169V + V173M (n=1); L180M + M204V + V173L (n=1); L180M + M204V + V173L + M250V (n=1); M204I + V214A + P237H (n=1). The cumulative occurrence rates of genotypic resistance to ETV were not significantly different between CHB patients with prior nucleos(t)tide analogues (NA) exposure (NA experienced, n=56) and NA naïve patients (n=202, P=0.823 by log rank comparison). Older age, higher baseline log10hepatitis B virus-deoxynucleic acid (log10HBV-DNA), higher log10HBV-DNA at 3, 6, 12 and 24 months after baseline, and complete virologic response (CVR, undetectable serum HBV-DNA by polymerase chain reaction 6 months after ETV treatment) were significant contributors to the development of genotypic resistance to ETV. Multivariate analyses showed higher log10HBV-DNA 6 months after baseline and absence of CVR were independent and significant contributors to the development of ETV resistance.
Conclusions
Clinical characteristics of patients who developed ETV resistance were higher log10HBV-DNA 6 months after baseline and absence of CVR during the ETV treatment.

Citations

Citations to this article as recorded by  Crossref logo
  • Specific association and independent predictive value of HBV RNA in the disease progression of hepatitis B with low-level viremia
    Liang Xu, Bin Yin, Dandan Chen, Xia Xiong, Yongfeng Yang, Xuping Wu
    Clinics and Research in Hepatology and Gastroenterology.2025; 49(7): 102648.     CrossRef
  • Effectiveness and safety of tenofovir alafenamide in chronic hepatitis B patients over 30 years old with positive hepatitis B virus DNA: a double-center retrospective study
    Yinong Feng, Li Zhou, Shaoyuan Shi, Zehong Wang, Xuanxuan Wang, Fan Du
    Frontiers in Medicine.2025;[Epub]     CrossRef
  • Risk factors related to low-level viraemia in chronic hepatitis B patients receiving entecavir treatment
    Zhong-Bin Li, Dan-Dan Chen, Yun-Fei Jia, Qing-Juan He, Li Cui, Feng-Xia Du, Yao-Jie Kang, Xin Feng, Mengwen He, Xue-Yuan Jin, Jing Chen, Yudong Wang, Dong Ji, George Lau, Shu-Gao Wu
    Frontiers in Cellular and Infection Microbiology.2024;[Epub]     CrossRef
  • Risk factors of low‐level viremia in chronic hepatitis B patients receiving Entecavir monotherapy: a retrospective cohort study
    He Chen, Juan‐Juan Fu, Li Li, Xia Wang, Xiu‐Cheng Pan
    Journal of Gastroenterology and Hepatology.2024; 39(1): 180.     CrossRef
  • A systematic review and meta-analysis of the risk of hepatitis B virus (HBV) resistance in people treated with entecavir or tenofovir
    Sheila F. Lumley, Marion Delphin, Jolynne F. Mokaya, Cedric C.S. Tan, Emily Martyn, Motswedi Anderson, Ka Chun Li, Elizabeth Waddilove, Gloria Sukali, Louise O. Downs, Khadija Said, Dorcas Okanda, Cori Campbell, Eli Harriss, Yusuke Shimakawa, Philippa C.
    Journal of Clinical Virology.2024; 174: 105711.     CrossRef
  • The urgency to expand the antiviral indications of general chronic hepatitis B patients
    Ping Fan, Lan-Qing Li, En-Qiang Chen
    Frontiers in Medicine.2023;[Epub]     CrossRef
  • Research Progress of Low-Level Viraemia in Patients with Chronic Hepatitis B
    祥运 张
    Advances in Clinical Medicine.2023; 13(12): 20083.     CrossRef
  • The association of the heterogeneity of HBV reverse transcriptase quasispecies with antiviral efficacy after treatment with nucleos(t)ide analogues for 10 years
    Tai-Cheng Zhou, Feng-Wei Liu, Jing-Hua Fan, Si-Hang Zhang, Song-Qin Lv, Zhi-Yong Yu, Yan-Mei Zhang, Liang Zhang, Jia Wei
    Infection, Genetics and Evolution.2021; 89: 104706.     CrossRef
  • Detection of Hepatitis B Virus M204V Mutation Quantitatively via Real-time PCR
    Jingjing Liang, Xinmiao Liang, Hong Ma, Leng Nie, Ying Tian, Guang Chen, Yu Wang
    Journal of Clinical and Translational Hepatology.2021; 000(000): 000.     CrossRef
  • Hepatitis B virus resistance to tenofovir: fact or fiction? A systematic literature review and structural analysis of drug resistance mechanisms
    Jolynne Mokaya, Anna L. McNaughton, Phillip A Bester, Dominique Goedhals, Eleanor Barnes, Brian D Marsden, Philippa C. Matthews
    Wellcome Open Research.2020; 5: 151.     CrossRef
  • Current state-of-the-art pharmacotherapy for the management of hepatitis B infection
    Hans L. Tillmann, Gbeminiyi Samuel
    Expert Opinion on Pharmacotherapy.2019; 20(7): 873.     CrossRef
  • Entecavir

    Reactions Weekly.2018; 1688(1): 98.     CrossRef
  • Is it possible to predict the development of an entecavir resistance mutation in patients with chronic hepatitis B in clinical practice?
    Joon Yeul Nam, Jeong-Hoon Lee
    Clinical and Molecular Hepatology.2017; 23(4): 311.     CrossRef
  • 10,510 View
  • 185 Download
  • 10 Web of Science
  • Crossref

Viral hepatitis

Comparison of the clinical outcomes between antiviral-naïve patients treated with entecavir and lamivudine-resistant patients receiving adefovir add-on lamivudine combination treatment
Hong Joo Kim, Soo Kyung Park, Hyo Joon Yang, Yoon Suk Jung, Jung Ho Park, Dong Il Park, Yong Kyun Cho, Chong Il Sohn, Woo Kyu Jeon, Byung Ik Kim, Kyu Yong Choi
Clin Mol Hepatol 2016;22(3):350-358.
Published online September 25, 2016
DOI: https://doi.org/10.3350/cmh.2016.0019
Background/Aims
To analyze the effects of preexisting lamivudine (LAM) resistance and applying antiviral treatment (adefovir [ADV] add-on LAM combination treatment) on long-term treatment outcomes, and comparing the clinical outcomes of antiviral-naïve chronic hepatitis B patients receiving entecavir (ETV) monotherapy.
Methods
This study enrolled 73 antiviral-naïve patients who received 0.5-mg ETV as an initial therapy and 54 patients who received ADV add-on LAM combination treatment as a rescue therapy from July 2006 to July 2010.
Results
During 24-month treatments, the decreases in serum log10HBV-DNA values (copies/mL) were significantly greater in the antiviral-naïve patients treated with ETV than the patients receiving ADV add-on LAM combination treatment. The biochemical response rates for alanine aminotransferase normalization at 6 months (ETV) and 12 months (ADV add-on LAM) were 90.4% (66/73) and 77.8% (42/54), respectively (P=0.048). A Kaplan-Meier analysis indicated that the rates of serologic response, viral breakthrough, and emergence of genotypic resistance did not differ significantly between the two patient groups. There were also no significant intergroup differences in the rates of disease progression (PD) and new development of hepatocellular carcinoma (HCC).
Conclusions
The long-term clinical outcomes of antiviral-naïve patients treated with ETV and LAM-resistant patients receiving ADV add-on LAM combination treatment were comparable in terms of the emergence of HCC and disease progression.

Citations

Citations to this article as recorded by  Crossref logo
  • Efficacy and cost-effectiveness of antiviral regimens for entecavir-resistant hepatitis B: A systematic review and network meta-analysis
    Si-Si Yang, Cheng-Wei Cai, Xue-Qing Ma, Jia Xu, Cheng-Bo Yu
    Hepatobiliary & Pancreatic Diseases International.2020; 19(6): 507.     CrossRef
  • 11,638 View
  • 142 Download
  • 1 Web of Science
  • Crossref

Steatotic liver disease

Elevated red cell distribution width is associated with advanced fibrosis in NAFLD
Hwa Mok Kim, Bum Soo Kim, Yong Kyun Cho, Byung Ik Kim, Chong Il Sohn, Woo Kyu Jeon, Hong Joo Kim, Dong Il Park, Jung Ho Park, Kwan Joong Joo, Chang Joon Kim, Yong Sung Kim, Woon Je Heo, Won Seok Choi
Clin Mol Hepatol 2013;19(3):258-265.
Published online September 30, 2013
DOI: https://doi.org/10.3350/cmh.2013.19.3.258
Background/Aims

The red-blood-cell distribution width (RDW) is a newly recognized risk marker in patients with cardiovascular disease, but its role in nonalcoholic fatty liver disease (NAFLD) has not been well defined. The aim of the present study was to determine the association between RDW values and the level of fibrosis in NAFLD according to BARD and FIB-4 scores.

Methods

This study included 24,547 subjects who had been diagnosed with NAFLD based on abdominal ultrasonography and questionnaires about alcohol consumption. The degree of liver fibrosis was determined according to BARD and FIB-4 scores. The association between RDW values and the degree of fibrosis in NAFLD was analyzed retrospectively.

Results

After adjusting for age, hemoglobin level, mean corpuscular volume, history of hypertension, history of diabetes, and high-sensitivity C-reactive protein, the RDW values were 12.61±0.41% (mean±SD), 12.70±0.70%, 12.77±0.62%, 12.87±0.82%, and 13.25±0.90% for those with BARD scores of 0, 1, 2, 3, and 4, respectively, and 12.71±0.72%, 12.79±0.66%, and 13.23±1.52% for those with FIB-4 scores of <1.30, 1.31-2.66, and ≥2.67, respectively (P<0.05). The prevalence of advanced fibrosis (BARD score of 24 and FIB-4 score of ≥1.3) increased with the RDW [BARD score: 51.1% in quartile 1 (Q1) vs. 63.6% in Q4; FIB-4 score: 6.9% in Q1 vs. 10.5% in Q4; P<0.001]. After adjustments, the odds ratio of having advanced fibrosis for those in Q4 compared to Q1 were 1.76 (95%CI=1.55-2.00, P<0.001) relative to BARD score and 1.69 (95%CI=1.52-1.98, P<0.001) relative to FIB-4 score.

Conclusions

Elevated RDW is independently associated with advanced fibrosis in NAFLD.

Citations

Citations to this article as recorded by  Crossref logo
  • Letter to the Editor: Hematological traits in sodium-glucose cotransporter-2 efficacy: Mediators or confounders?
    Yuanhao Wei, Lanlan Chen, Kun Zhao
    Hepatology.2025; 81(3): E99.     CrossRef
  • Novel integrative models to predict the severity of inflammation and fibrosis in patients with drug-induced liver injury
    Yue Zhang, Chuan Lu, Jingying Xu, Qiqi Ma, Mei Han, Li Ying
    Frontiers in Medicine.2025;[Epub]     CrossRef
  • Prognostic significance of red cell distribution width to albumin ratio in ICU patients with Non-alcoholic fatty liver disease: a retrospective analysis
    Huan Yang, Libo Liang, Yan Liu, Xia Wang, Jinling Li, Xiao Du, He He
    BMC Gastroenterology.2025;[Epub]     CrossRef
  • A potential age-independent MASLD-related liver fibrosis index based on metabolic profiling
    Serena Zampieri, Greta Petrella, Elisa Nagni, Laura Micheli, Francesca Maiorca, Ludovica Lombardi, Marilena Carbone, Annamaria Sabetta, Marzia Miglionico, Marin Pecani, Valeria Raparelli, Stefania Basili, Lucia Stefanini, Daniel Oscar Cicero, Adriano Pell
    Scientific Reports.2025;[Epub]     CrossRef
  • Increased frequencies of human Th-17 CD4+ T-cells and decreased T-regulatory cells in patients with early and advanced metabolic dysfunction-associated steatotic liver disease
    Elżbieta Supruniuk, Kamil Grubczak, Anna Parfieniuk-Kowerda, Robert Flisiak, Marcin Moniuszko, Jerzy Jaroszewicz, Adrian Chabowski, Magdalena Świderska
    Frontiers in Immunology.2025;[Epub]     CrossRef
  • Hepatic Hydrothorax: A Contemporary Review for Pleural Physicians
    Yasmin Rahim, Raja Reddy
    Current Pulmonology Reports.2025;[Epub]     CrossRef
  • Association between body roundness index and risk of ultrasound-defined non-alcoholic fatty liver disease
    Enfa Zhao, Xiaolin Wen, Wenqian Qiu, Chaoxue Zhang
    Heliyon.2024; 10(1): e23429.     CrossRef
  • The Role of Red Cell Distribution Width as a Prognostic Marker in Chronic Liver Disease: A Literature Review
    Hunain Aslam, Fouzia Oza, Khalid Ahmed, Jonathan Kopel, Mark M. Aloysius, Aman Ali, Dushyant Singh Dahiya, Muhammad Aziz, Abhilash Perisetti, Hemant Goyal
    International Journal of Molecular Sciences.2023; 24(4): 3487.     CrossRef
  • An easy-to-use AIHF-nomogram to predict advanced liver fibrosis in patients with autoimmune hepatitis
    Zhiyi Zhang, Jian Wang, Huali Wang, Yuanwang Qiu, Li Zhu, Jiacheng Liu, Yun Chen, Yiguang Li, Yilin Liu, Yuxin Chen, Shengxia Yin, Xin Tong, Xiaomin Yan, Yali Xiong, Yongfeng Yang, Qun Zhang, Jie Li, Chuanwu Zhu, Chao Wu, Rui Huang
    Frontiers in Immunology.2023;[Epub]     CrossRef
  • Evaluation of Hematological Biomarkers in Childhood Metabolic Dysfunction Associated Steatotic Liver Disease
    Meltem GÜMÜŞ, Alaaddin YORULMAZ, Hakan CANDAN, Mehmet ÖZTÜRK, Fuat BUĞRUL, Halil Haldun EMİROĞLU
    Journal of Contemporary Medicine.2023; 13(5): 1024.     CrossRef
  • Prevalence and Crucial Parameters in Diabesity-Related Liver Fibrosis: A Preliminary Study
    Szymon Suwała, Aleksandra Białczyk, Kinga Koperska, Alicja Rajewska, Magdalena Krintus, Roman Junik
    Journal of Clinical Medicine.2023; 12(24): 7760.     CrossRef
  • Association of Hematological Parameters (Mean Platelet Volume and Red Cell Distribution Width) with Nonalcoholic Fatty Liver Disease
    Sonika Verma, Manish Verma, Sunny Khari
    APIK Journal of Internal Medicine.2023; 11(1): 37.     CrossRef
  • The relationship between red cell distribution width and prognostic scores in myelodysplastic syndrome
    Atakan Turgutkaya, Nesim Akın, Gökhan Sargın, Zahit Bolaman, İrfan Yavaşoğlu
    Hematology, Transfusion and Cell Therapy.2022; 44(3): 332.     CrossRef
  • Brewed chicory leaf consumption has unexpected side effects along beneficial effects on liver enzymes in non-alcoholic fatty liver disease patients
    Samira Faraji, Mohammad Reza Mohammad Hosseini Azar, Mohammad Alizadeh
    Journal of Herbal Medicine.2022; 34: 100572.     CrossRef
  • The fibrosis‐4 score is associated with long‐term mortality in different phenotypes of acute heart failure
    Chih‐Hsueh Tseng, Wei‐Min Huang, Wen‐Chung Yu, Hao‐Min Cheng, Hao‐Chih Chang, Pai‐Feng Hsu, Chern‐En Chiang, Chen‐Huan Chen, Shih‐Hsien Sung
    European Journal of Clinical Investigation.2022;[Epub]     CrossRef
  • Increased red cell distribution width predicts severity of drug-induced liver injury: a retrospective study
    Xu Li, Hongqin Xu, Pujun Gao
    Scientific Reports.2021;[Epub]     CrossRef
  • Accuracy of gamma-glutamyl transpeptidase-to-platelet ratio (GPR), red cell distribution width (RDW), aspartate aminotransferase-to-platelet ratio index (APRI), and the fibrosis-4 index (FIB4) compared with liver biopsy in patients with drug-induced liver
    Minjie Wan, Hongqin Xu, Dezhao Li, Le Wang, Xu Li
    Medicine.2021; 100(6): e24723.     CrossRef
  • Nonlinear Relationship Between Macrocytic Anemia and Decompensated Hepatitis B Virus Associated Cirrhosis: A Population-Based Cross-Sectional Study
    Tian-Yu Zhao, Qing-Wei Cong, Fang Liu, Li-Ying Yao, Ying Zhu
    Frontiers in Pharmacology.2021;[Epub]     CrossRef
  • Red blood cell distribution width: A promising index for evaluating the severity and long-term prognosis of hepatitis B virus–related diseases
    Jian Wang, Rui Huang, Xiaomin Yan, Ming Li, Yuxin Chen, Juan Xia, Yong Liu, Bei Jia, Li Zhu, Zhaoping Zhang, Chuanwu Zhu, Chao Wu
    Digestive and Liver Disease.2020; 52(4): 440.     CrossRef
  • Red cell distribution width to platelet ratio predicts liver fibrosis in patients with autoimmune hepatitis
    Huali Wang, Jian Wang, Juan Xia, Xiaomin Yan, Yanhong Feng, Lin Li, Jun Chen, Duxian Liu, Weimao Ding, Yongfeng Yang, Rui Huang, Chao Wu
    Medicine.2020; 99(34): e21408.     CrossRef
  • Effects of oleoylethanolamide supplementation on atherogenic indices and hematological parameters in patients with nonalcoholic fatty liver disease: A clinical trial
    Helda Tutunchi, Fatemeh Naeini, Maryam Saghafi-Asl, Nazila Farrin, Alireza Monshikarimi, Alireza Ostadrahimi
    Health Promotion Perspectives.2020; 10(4): 373.     CrossRef
  • Association between red cell distribution width-to-platelet ratio and hepatic fibrosis in nonalcoholic fatty liver disease
    Wen-Jie Zhou, Jing Yang, Ge Zhang, Zheng-Qiang Hu, Yong-Mei Jiang, Fan Yu
    Medicine.2019; 98(30): e16565.     CrossRef
  • Red cell distribution width to platelet ratio for liver fibrosis: a systematic review and meta-analysis of diagnostic accuracy
    Gerasimos P. Milas, Vasilios Karageorgiou, Evangelos Cholongitas
    Expert Review of Gastroenterology & Hepatology.2019; 13(9): 877.     CrossRef
  • Red blood cell distribution width for predicting significant liver inflammation in patients with autoimmune hepatitis
    Huali Wang, Jian Wang, Rui Huang, Juan Xia, Lingyun Zuo, Xiaomin Yan, Yongfeng Yang, Chao Wu
    European Journal of Gastroenterology & Hepatology.2019; 31(12): 1527.     CrossRef
  • Macrocytic anemia is associated with the severity of liver impairment in patients with hepatitis B virus-related decompensated cirrhosis: a retrospective cross-sectional study
    Jian Yang, Bin Yan, Lihong Yang, Huimin Li, Yajuan Fan, Feng Zhu, Jie Zheng, Xiancang Ma
    BMC Gastroenterology.2018;[Epub]     CrossRef
  • The role of red cell distribution width as a noninvasive index for predicting liver cell failure and portal hypertension in cirrhotic patients
    Howaida A. Nafady, Tarek A. Hassan, Lobna A. Ahmed, Marina A. Waheeb
    The Egyptian Journal of Internal Medicine.2018; 30(4): 255.     CrossRef
  • Preliver transplant red cell distribution width predicts postliver transplant mortality
    M. Thure Caire, Ambuj Kumar, R. Todd Stravitz, Nyingi Kemmer
    Clinical Transplantation.2017;[Epub]     CrossRef
  • Red cell distribution width as a significant indicator of medication and prognosis in type 2 diabetic patients
    Xiao-fen Xiong, Yuan Yang, Xianghui Chen, Xuejing Zhu, Chun Hu, Yachun Han, Li Zhao, Fuyou Liu, Lin Sun
    Scientific Reports.2017;[Epub]     CrossRef
  • Elevated Hemoglobin Level Is Associated With Advanced Fibrosis in Pediatric Nonalcoholic Fatty Liver Disease
    Valentina Giorgio, Antonella Mosca, Arianna Alterio, Anna Alisi, Antonio Grieco, Valerio Nobili, Luca Miele
    Journal of Pediatric Gastroenterology and Nutrition.2017; 65(2): 150.     CrossRef
  • Prognostic significance of red blood cell distribution width in gastrointestinal disorders
    Hemant Goyal, Giuseppe Lippi, Altin Gjymishka, Bijo John, Rajiv Chhabra, Elizabeth May
    World Journal of Gastroenterology.2017; 23(27): 4879.     CrossRef
  • Diabetes and red blood cell parameters
    Jaman MS
    Annals of Clinical Endocrinology and Metabolism.2017; 2(1): 001.     CrossRef
  • Red Blood Cell Distribution Width Levels Correlate With Liver Fibrosis and Inflammation
    Wen-Shen Xu, Xiao-Ming Qiu, Qi-shui Ou, Can Liu, Jin-Piao Lin, Hui-Juan Chen, Sheng Lin, Wen-Hua Wang, Shou-Rong Lin, Jing Chen
    Medicine.2015; 94(10): e612.     CrossRef
  • Reduced Red Blood Cell Count Predicts Poor Survival After Surgery in Patients With Primary Liver Cancer
    Xiaomeng Xie, Mingjie Yao, Xiangmei Chen, Weiquan Lu, Quanjun Lv, Kaijuan Wang, Ling Zhang, Fengmin Lu
    Medicine.2015; 94(8): e577.     CrossRef
  • Red blood cell distribution width: A simple parameter with multiple clinical applications
    Gian Luca Salvagno, Fabian Sanchis-Gomar, Alessandra Picanza, Giuseppe Lippi
    Critical Reviews in Clinical Laboratory Sciences.2015; 52(2): 86.     CrossRef
  • Utility of RDW in Prediction of Strangulation in Emergency Setting Hernias
    Okan Akturk, Baris Dogu Yildiz, Melih Karabeyoglu, Isıl Karabeyoglu
    International Surgery.2015; 100(9-10): 1262.     CrossRef
  • Red cell distribution width as a potential index to assess the severity of hepatitis B virus‐related liver diseases
    Rui Huang, Chenchen Yang, Kangkang Wu, Shufeng Cao, Yong Liu, Ran Su, Yali Xiong, Aijun Huang, Chao Wu
    Hepatology Research.2014;[Epub]     CrossRef
  • Serum amylase levels are decreased in Chinese non-alcoholic fatty liver disease patients
    Jinmei Yao, Ying Zhao, Juanwen Zhang, Yani Hong, Huanle Lu, Jianping Wu
    Lipids in Health and Disease.2014;[Epub]     CrossRef
  • Assessment of the relationship between red cell distribution width and fragmented QRS in patients with non-ST elevated acute coronary syndrome
    Mustafa Yılmaz
    Medical Science Monitor.2014; 20: 413.     CrossRef
  • Red cell distribution width and nonalcoholic steatohepatitis
    Yasemin Gulcan Kurt, Tuncer Cayci, Fevzi Nuri Aydin, Mehmet Agilli
    World Journal of Gastroenterology.2014; 20(43): 16387.     CrossRef
  • Chasing after novel non-invasive markers to identify advanced fibrosis in NAFLD
    Wonseok Kang, Seung Up Kim
    Clinical and Molecular Hepatology.2013; 19(3): 255.     CrossRef
  • 13,214 View
  • 114 Download
  • Crossref

Steatotic liver disease

The influence of waist circumference on insulin resistance and nonalcoholic fatty liver disease in apparently healthy Korean adults
Deok Yun Ju, Young Gil Choe, Yong Kyun Cho, Dong Suk Shin, Su Hyeon Yoo, Seo Hyoung Yim, Ji Yong Lee, Jung Ho Park, Hong Joo Kim, Dong Il Park, Chong Il Sohn, Woo Kyu Jeon, Byung Ik Kim
Clin Mol Hepatol 2013;19(2):140-147.
Published online June 27, 2013
DOI: https://doi.org/10.3350/cmh.2013.19.2.140
Background/Aims

Waist circumference (WC) is a risk factor for metabolic syndrome and is related to insulin resistance (IR) and nonalcoholic fatty liver disease (NAFLD). The purpose of this study was to determine the association between WC and IR and NAFLD in apparently healthy Korean adults.

Methods

The volunteers included in this cross-sectional study comprised 9,159 adults (5,052 men, 4,107 women) who participated in a comprehensive health checkup program. IR was evaluated by the homeostasis model assessment of IR (HOMA-IR) and was considered to be present when the HOMA-IR score was >2. NAFLD was evaluated by ultrasound examination. Elevated alanine aminotransferase (ALT) was defined as >40 IU/L in men and >35 IU/L in women. Logistic regression was performed to determine the odds ratios (ORs) and 95% confidence intervals (95% CIs) for NAFLD, IR, and ALT according to categorized levels of WC.

Results

NAFLD was found in 2,553 (27.9%) of the participants (82.6% men, 17.4% women), while IR and elevated ALT were found in 17.2% (68.1% men, 31.9% women) and 10% (83% men, 17% women), respectively. After adjusting for confounding factors, the prevalence of NAFLD, IR, and elevated ALT was significantly associated with increases in WC quartile: highest quartile for NAFLD in men, OR=15.539, 95% CI=12.687-19.033; highest quartile for NAFLD in women, OR=48.732, 95% CI=23.918-99.288 (P<0.001); and highest quartile for IR in men, OR=17.576, 95% CI=13.283-23.255; highest quartile for IR in women, OR=11.078, 95% CI=7.813-15.708 (P<0.001); highest quartile for elevated ALT in men, OR=7.952, 95% CI=6.046-10.459; and highest quartile for elevated ALT in women, OR=8.487, 95% CI=4.679-15.395 (P<0.001).

Conclusions

WC contributes to IR and NAFLD in apparently healthy Korean adults, and thus may be an important factor in the development of IR and NAFLD.

Citations

Citations to this article as recorded by  Crossref logo
  • Association between TyG-related parameters and NAFLD risk in Japanese non-obese population
    Xiuli Wang, Jie Liu, Ke Yu, Zhenhua Huang, Hanxiong Liu, Xiang Li
    Scientific Reports.2025;[Epub]     CrossRef
  • Platelet-derived growth factor receptor-β as a non-invasive biomarker for liver fibrosis prediction in Egyptian diabetic patients with metabolic-associated fatty liver disease
    Hanaa Badran, Maha Elsabaawy, Mai Magdy, Hazem Omar, Olfat Hendy, Eman Awaad, Maymona Abd El-Wahed Al-Khalifa, Mai Abozeid
    BMC Gastroenterology.2025;[Epub]     CrossRef
  • Study of association and diagnostic utility of novel anthropometric and lipid indices for nonalcoholic fatty liver disease: A hospital-based study
    Anand K. Pyati, Sakthivadivel Varatharajan, Abhishek Arora, Vaman Kulkarni, Aparna Varma Bhongir, Sangeetha Sampath, Gomathi Ramaswamy, Madhu Latha Karra, Priyanka Das, Pawan Pagaku
    Journal of Family Medicine and Primary Care.2025; 14(6): 2365.     CrossRef
  • Global prevalence of insulin resistance in the adult population: a systematic review and meta-analysis
    Jhosmer Ballena-Caicedo, Fiorella E. Zuzunaga-Montoya, Joan A. Loayza-Castro, Juan Carlos Bustamante-Rodríguez, Luisa Erika Milagros Vásquez Romero, Rafael Tapia-Limonchi, Carmen Inés Gutierrez De Carrillo, Víctor Juan Vera-Ponce
    Frontiers in Endocrinology.2025;[Epub]     CrossRef
  • Exploring The Impact of Dietary and Metabolic Risk Factors on Non-Alcoholic Fatty Liver Disease (NAFLD) : A Cross-Sectional Study
    İzel Aycan Orakçı, İlyas Tuncer, Fatma Esra Güneş
    Turkish Journal of Health Science and Life.2025; 8(2): 29.     CrossRef
  • Garlic ( Allium sativum L. ) in diabetes and its complications: Recent advances in mechanisms of action
    Yayi Jiang, Rensong Yue, Guojie Liu, Jun Liu, Bo Peng, Maoyi Yang, Lianxue Zhao, Zihan Li
    Critical Reviews in Food Science and Nutrition.2024; 64(16): 5290.     CrossRef
  • Validity of fatty liver prediction scores for diagnosis of fatty liver by Fibroscan
    Seogsong Jeong, Sun Jae Park, Seong Kyun Na, Sang Min Park, Byung-Cheol Song, Yun Hwan Oh
    Hepatobiliary & Pancreatic Diseases International.2024; 23(4): 353.     CrossRef
  • Effectiveness of the ALT/AST ratio for predicting insulin resistance in a Korean population: A large-scale, cross-sectional cohort study
    Seul Ki Han, Myung Jae Seo, Taesic Lee, Moon Young Kim, Anna Di Sessa
    PLOS ONE.2024; 19(5): e0303333.     CrossRef
  • Regional fat distribution and hepatic fibrosis and steatosis severity in patients with nonalcoholic fatty liver disease and type 2 diabetes
    Asieh Mansour, Saeed Pourhassan, Hadis Gerami, Mohammad Reza Mohajeri‐Tehrani, Marziye Salahshour, Ali Abbasi, Elham Madreseh, Sayed Mahmoud Sajjadi‐Jazi
    Obesity Science & Practice.2024;[Epub]     CrossRef
  • Waist to height ratio in nonalcoholic fatty liver disease – Systematic review and meta-analysis
    Abdulrahman Ismaiel, Blal El Hosiny, Mohamed Ismaiel, Daniel-Corneliu Leucuta, Stefan-Lucian Popa, Cristina Sorina Catana, Dan L. Dumitrascu
    Clinics and Research in Hepatology and Gastroenterology.2023; 47(7): 102160.     CrossRef
  • Is There any Need for the Early Detection of Non-alcoholic Fatty Liver Disease in Children with Type 1 Diabetes Mellitus?
    Soodeh Salehi, Sanaz Mehrpour, Shahin Koohmanaee, Shohreh Maleknejad, Mohammad Ali Esfandiari, Saman Maroufizadeh, Setila Dalili, Afagh Hassanzadeh Rad
    Hepatitis Monthly.2023;[Epub]     CrossRef
  • Metabolic and Risk Profiles of Lean and Non-Lean Hepatic Steatosis among US Adults
    Meiling Li, Weiping Zhang, Xiude Li, Shaoxian Liang, Yaozong Zhang, Yufeng Mo, Songxian Rao, Honghua Zhang, Yong Huang, Yu Zhu, Zhuang Zhang, Wanshui Yang
    Nutrients.2023; 15(13): 2856.     CrossRef
  • Neck Circumference as a Predictor of Insulin Resistance in People with Non-alcoholic Fatty Liver Disease
    Da-Hye Son, Jee Hye Han, Jun-Hyuk Lee
    Journal of Obesity & Metabolic Syndrome.2023; 32(3): 214.     CrossRef
  • Association between waist circumference trajectories and incident non-alcoholic fatty liver disease
    Jun-Hyuk Lee, Soyoung Jeon, Hye Sun Lee, Yu-Jin Kwon
    Obesity Research & Clinical Practice.2023; 17(5): 398.     CrossRef
  • Comparison of bioelectrical impedance analysis, mass index, and waist circumference in assessing risk for non-alcoholic steatohepatitis
    Katherine J.P. Schwenger, Alexander Kiu, Maryam AlAli, Amnah Alhanaee, Sandra E. Fischer, Johane P. Allard
    Nutrition.2022; 93: 111491.     CrossRef
  • The value of combining the simple anthropometric obesity parameters, Body Mass Index (BMI) and a Body Shape Index (ABSI), to assess the risk of non-alcoholic fatty liver disease
    Maobin Kuang, Guotai Sheng, Chong Hu, Song Lu, Nan Peng, Yang Zou
    Lipids in Health and Disease.2022;[Epub]     CrossRef
  • IS HOMEOSTASIS MODEL ASSESSMENT FOR INSULIN RESISTANCE >2.5 A DISTINGUISHED CRITERIA FOR METABOLIC DYSFUNCTION-ASSOCIATED FATTY LIVER DISEASE IDENTIFICATION?
    Bárbara Ferreira de Mello BARRETO, Giovana Rita PUNARO, Maria Cristina ELIAS, Edison Roberto PARISE
    Arquivos de Gastroenterologia.2022; 59(3): 402.     CrossRef
  • Identify Functional lncRNAs in Nonalcoholic Fatty Liver Disease by Constructing a ceRNA Network
    Wei Xue, Jia Zhang, Yali Zhu, Wenxiang Huang
    ACS Omega.2022; 7(26): 22522.     CrossRef
  • Anthropometric clinical indicators of visceral adiposity as predictors of nonalcoholic fatty liver disease
    Naiade Silveira Almeida, Raquel Rocha, Carla Daltro, Claudineia Almeida de Souza, Rafael Leiróz Pereira Duarte Silva, Manoel Alfredo Curvelo Sarno, Helma Pinchemel Cotrim
    Revista da Associação Médica Brasileira.2021; 67(11): 1544.     CrossRef
  • Waist-to-height ratio, an optimal anthropometric indicator for metabolic dysfunction associated fatty liver disease in the Western Chinese male population
    Jinwei Cai, Cuiting Lin, Shuiqing Lai, Yingshan Liu, Min Liang, Yingfen Qin, Xinghuan Liang, Aihua Tan, Yong Gao, Zheng Lu, Chunlei Wu, Shengzhu Huang, Xiaobo Yang, Haiying Zhang, Jian Kuang, Zengnan Mo
    Lipids in Health and Disease.2021;[Epub]     CrossRef
  • Comparison of Body Mass Index and Fat Indices in Predicting the Severity of Nonalcoholic Fatty Liver Disease Among Children Who Are Overweight and Obese
    Hsun-Chin Chao, Hsin-Yeh Lin
    Frontiers in Pediatrics.2021;[Epub]     CrossRef
  • Influence of Besifovir Dipivoxil Maleate Combined with L-Carnitine on Hepatic Steatosis in Patients with Chronic Hepatitis B
    Yeon Woo Jung, Moonhyun Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Seung Up Kim
    Journal of Korean Medical Science.2020;[Epub]     CrossRef
  • Mortality of NAFLD According to the Body Composition and Presence of Metabolic Abnormalities
    Pegah Golabi, James M. Paik, Tamoore Arshad, Youssef Younossi, Alita Mishra, Zobair M. Younossi
    Hepatology Communications.2020; 4(8): 1136.     CrossRef
  • Analysis of Metabolic Biomarkers in Non-Alcoholic Fatty Liver Disease (NAFLD); A Comprehensive Review
    Shagufta Akhtar, Azhar Khan
    Advanced Journal of Graduate Research.2020; 9(1): 46.     CrossRef
  • Clinical, Anthropometric, Biochemical and Histological Character of Nonalcoholic Fatty Liver Disease Without Insulin Resistance
    Shahinul Alam, Kamrul Anam, Saiful Islam, Golam Mustafa, Ayub Al Mamun, Nooruddin Ahmad
    Journal of Clinical and Experimental Hepatology.2019; 9(2): 176.     CrossRef
  • Body mass index and the visceral adipose tissue expression of IL-6 and TNF-alpha are associated with the morphological severity of non-alcoholic fatty liver disease in individuals with class III obesity
    Antônio Sérgio Barcala Jorge, João Marcus Oliveira Andrade, Alanna Fernandes Paraíso, Gislaine Candida Batista Jorge, Christine Mendes Silveira, Ludmilla Regina de Souza, Erivelton Pereira Santos, André Luiz Sena Guimaraes, Sérgio Henrique Sousa Santos, A
    Obesity Research & Clinical Practice.2018; 12(1): 1.     CrossRef
  • Anthropometric indicators of visceral adiposity as predictors of non-alcoholic fatty liver disease: A review
    Naiade Silveira Almeida, Raquel Rocha, Helma Pinchemel Cotrim, Carla Daltro
    World Journal of Hepatology.2018; 10(10): 695.     CrossRef
  • Circunferência da cintura como marcador para triagem de doença hepática gordurosa não alcoólica em adolescentes obesos
    Ana Paula Grotti Clemente, Bárbara Dal Molin Netto, Joana Pereira de Carvalho‐Ferreira, Raquel Munhoz da Silveira Campos, Aline de Piano Ganen, Lian Tock, Marco Túlio de Mello, Ana Raimunda Dâmaso
    Revista Paulista de Pediatria.2016; 34(1): 47.     CrossRef
  • Waist circumference as a marker for screening nonalcoholic fatty liver disease in obese adolescents
    Ana Paula Grotti Clemente, Bárbara Dal Molin Netto, Joana Pereira de Carvalho-Ferreira, Raquel Munhoz da Silveira Campos, Aline de Piano Ganen, Lian Tock, Marco Túlio de Mello, Ana Raimunda Dâmaso
    Revista Paulista de Pediatria (English Edition).2016; 34(1): 47.     CrossRef
  • Relationship of Colorectal Polyps and Fatty Liver Disease Diagnosed by Ultrasonography
    Hye-Nam Lee, Cheong-Hwan Lim, Hong-Ryang Jung
    Journal of Digital Convergence.2014; 12(3): 345.     CrossRef
  • Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation
    Xing-Chun Wang
    World Journal of Gastroenterology.2014; 20(40): 14821.     CrossRef
  • 11,056 View
  • 79 Download
  • Crossref

Liver fibrosis, cirrhosis, and portal hypertension

Is there any vindication for low dose nonselective β-blocker medication in patients with liver cirrhosis?
Tae Wan Kim, Hong Joo Kim, Chang Uk Chon, Hyun Sun Won, Jung Ho Park, Dong Il Park, Yong Kyun Cho, Chong Il Sohn, Woo Kyu Jeon, Byung Ik Kim
Korean J Hepatol 2012;18(2):203-212.
Published online June 26, 2012
DOI: https://doi.org/10.3350/cmh.2012.18.2.203
Background/Aims

Nonselective β-blockers (NSBBs), such as propranolol, reportedly exert a pleiotropic effect in liver cirrhosis. A previous report suggested that survival was higher in patients receiving adjusted doses of NSBBs than in ligation patients. This study investigated whether low-dose NSBB medication has beneficial effects in patients with liver cirrhosis, especially in terms of overall survival.

Methods

We retrospectively studied 273 cirrhotic patients (199 males; age 53.6±10.2 years, mean±SD) who visited our institution between March 2003 and December 2007; follow-up data were collected until June 2011. Among them, 138 patients were given a low-dose NSBB (BB group: propranolol, 20-60 mg/day), and the remaining 135 patients were not given an NSBB (NBB group). Both groups were stratified randomly according to Child-Turcotte-Pugh (CTP) classification and age.

Results

The causes of liver cirrhosis were alcohol (n=109, 39.9%), hepatitis B virus (n=125, 45.8%), hepatitis C virus (n=20, 7.3%), and cryptogenic (n=19, 7.0%). The CTP classes were distributed as follows: A, n=116, 42.5%; B, n=126, 46.2%; and C, n=31, 11.4%. Neither the overall survival (P=0.133) nor the hepatocellular carcinoma (HCC)-free survival (P=0.910) differed significantly between the BB and NBB groups [probability of overall survival at 4 years: 75.1% (95% CI=67.7-82.5%) and 81.2% (95% CI=74.4-88.0%), respectively; P=0.236]. In addition, the delta CTP score did not differ significantly between the two groups.

Conclusions

Use of low-dose NSBB medication in patients with liver cirrhosis is not indicated in terms of overall and HCC-free survival.

Citations

Citations to this article as recorded by  Crossref logo
  • Non-selective beta-blockers and the incidence of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis
    Xinyi He, Zimo Zhao, Xi Jiang, Yan Sun
    Frontiers in Pharmacology.2023;[Epub]     CrossRef
  • Association Between Nonselective Beta-Blocker Use and Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Without Cirrhosis and Decompensation
    He-Yun Cheng, Hsiu C. Lin, Hsiu L. Lin, Yow S. Uang, Joseph J. Keller, Li H. Wang
    Frontiers in Pharmacology.2022;[Epub]     CrossRef
  • Antitumor Effects and Mechanisms of Metabolic Syndrome Medications on Hepatocellular Carcinoma
    Kyoko Oura, Asahiro Morishita, Joji Tani, Tsutomu Masaki
    Journal of Hepatocellular Carcinoma.2022; Volume 9: 1279.     CrossRef
  • Low dose of propranolol treatment is associated with better survival in cirrhotic patients with hepatic encephalopathy
    Pei-Chang Lee, Yu-Ju Chen, Yueh-Ching Chou, Kuei-Chuan Lee, Ping-Hsien Chen, Wei-Yu Kao, Yi-Hsiang Huang, Teh-Ia Huo, Han-Chieh Lin, Ming-Chih Hou, Fa-Yauh Lee, Jaw-Ching Wu, Chien-Wei Su
    European Journal of Gastroenterology & Hepatology.2020; 32(3): 365.     CrossRef
  • Propranolol Is Associated with Lower Risk of Incidence of Hepatocellular Carcinoma in Patients with Alcoholic Cirrhosis: A Tertiary-Center Study and Indirect Comparison with Meta-Analysis
    Tzu-Hao Li, Yu-Lien Tsai, Chien-Fu Hsu, Chih-Wei Liu, Chia-Chang Huang, Ying-Ying Yang, Hung-Cheng Tsai, Shiang-Fen Huang, Yun-Cheng Hsieh, Hsuan-Miao Liu, Tzung-Yan Lee, Ming-Chih Hou, Chang-Youh Tsai, Han-Chieh Lin
    Gastroenterology Research and Practice.2020; 2020: 1.     CrossRef
  • Effect of Propranolol Treatment on the Incidence of Hepatocellular Carcinoma in Patients Waiting for Liver Transplant With Cirrhosis: A Retrospective, Surveillance Study in a Tertiary Center
    Nuretdin Suna, Diğdem Özer Etik, Serkan Öcal, Haldun Selçuk
    Experimental and Clinical Transplantation.2019; 17(5): 632.     CrossRef
  • Does Angiotensin‐Converting Enzyme Inhibitor and β‐Blocker Use Reduce the Risk of Primary Liver Cancer? A Case–Control Study Using the UK Clinical Practice Research Datalink
    Katrina Wilcox Hagberg, Vikrant V. Sahasrabuddhe, Katherine A. McGlynn, Susan S. Jick
    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy.2016; 36(2): 187.     CrossRef
  • The use of β-blockers is associated with a lower risk of developing hepatocellular carcinoma in patients with cirrhosis
    Iván Herrera, Sonia Pascual, Pedro Zapater, Fernando Carnicer, Pablo Bellot, José María Palazón
    European Journal of Gastroenterology & Hepatology.2016; 28(10): 1194.     CrossRef
  • Non‐selective beta‐blockers may reduce risk of hepatocellular carcinoma: a meta‐analysis of randomized trials
    Maja Thiele, Agustín Albillos, Rozeta Abazi, Reiner Wiest, Lise L. Gluud, Aleksander Krag
    Liver International.2015; 35(8): 2009.     CrossRef
  • Management of Hepatocellular Carcinoma in Cirrhotic Patients with Portal Hypertension: Relevance of Hagen-Poiseuille's Law
    Gerond Lake-Bakaar, Muneeb Ahmed, Amy Evenson, Alan Bonder, Salomao Faintuch, Vinay Sundaram
    Liver Cancer.2014; 3(3-4): 428.     CrossRef
  • Can non-selective beta-blockers prevent hepatocellular carcinoma in patients with cirrhosis?
    Maja Thiele, Reiner Wiest, Lise Lotte Gluud, Agustín Albillos, Aleksander Krag
    Medical Hypotheses.2013; 81(5): 871.     CrossRef
  • 10,283 View
  • 56 Download
  • Crossref
Chemical pleurodesis for the management of refractory hepatic hydrothorax in patients with decompensated liver cirrhosis
Woo Jin Lee, Hong Joo Kim, Jung Ho Park, Dong Il Park, Yong Kyun Cho, Chong Il Sohn, Woo Kyu Jeon, Byung Ik Kim
Korean J Hepatol 2011;17(4):292-298.
Published online December 26, 2011
DOI: https://doi.org/10.3350/kjhep.2011.17.4.292
Background/Aims

Hepatic hydrothorax in patients with decompensated liver cirrhosis is a challenging problem. Treatment with diuretics and intermittent thoracentesis can be effective in selected patients. However, there are few effective therapeutic options in patients who are intolerant of these therapies. This study investigated the clinical usefulness of chemical pleurodesis with or without video-assisted thoracoscopic surgery (VATS) for patients with refractory hepatic hydrothorax.

Methods

Eleven consecutive patients with refractory hepatic hydrothorax who underwent chemical pleurodesis with or without VATS between July 2007 and February 2011 were enrolled in this study. The medical records and radiologic imagings of these patients were thoroughly reviewed.

Results

The median number of chemical pleurodesis sessions performed was 3 (range: 2-10). Successful pleurodesis was achieved in 8 of the 11 patients (72.7%), 5 (62.5%) of whom remained asymptomatic and hydrothorax free for a median follow-up of 16 weeks (range: 2-52 weeks). Complications were low-grade fever/leukocytosis (n=11, 100%), pneumonia (n=1, 9.1%), pneumothorax (n=4, 36.4%), azotemia/acute renal failure (n=6, 54.6%), and hepatic encephalopathy (n=4, 36.4%). Five patients were suspected as having procedure-related mortality (45.5%) due to the occurrence of acute renal failure with hepatic failure. The overall survival was significantly longer in the success group than in the non-success group.

Conclusions

Although chemical pleurodesis may improve the clinical symptoms and the radiologic findings in as many as 72.7% of patients with refractory hepatic hydrothorax, a significantly high prevalence of procedure-related morbidity and mortality hinders the routine application of this procedure for such patients.

Citations

Citations to this article as recorded by  Crossref logo
  • Effective Management of Refractory Hepatic Hydrothorax With Hypertonic Glucose Pleurodesis
    Shuya Hashimoto, Toyoshi Yanagihara, Natsumi Kushima, Rei Sanai, Takato Ikeda, Naoki Hamada, Masaki Fujita
    Cureus.2025;[Epub]     CrossRef
  • Hepatic hydrothorax as a manifestation of decompensated cirrhosis: An update on current management and future directions
    Brandon-Joe Cilia, James Haridy, Ashok Raj, Nicholas Hannah
    World Journal of Hepatology.2025;[Epub]     CrossRef
  • Positionspapier für die standardisierte Anwendung von Transjugulärem Intrahepatischem Portosystemischem Shunt (TIPS) bei Erwachsenen
    Jonel Trebicka, Christian Steib, Alexander Zipprich, Cristina Ripoll, Johannes Kluwe, Michael Schultheiß, Andreas A. Schnitzbauer, Bernhard Meyer, Christian Jansen, Hauke Heinzow, Philipp Papprottka, Carsten Meyer, Max Seidensticker, Harald Ittrich, Frank
    Zeitschrift für Gastroenterologie.2025; 63(11): 1149.     CrossRef
  • Effectiveness of Chemical Pleurodesis Using Doxycycline in Malignant and Nonmalignant Pleural Disorders: A Retrospective Study from Rural South India
    Bimal Raj Rajalingam, Priya R Panicker, Archana L Peethambaran, Alexander Jenish Babu, Ravichandran Vijayakumar
    Indian Journal of Respiratory Care.2024; 12(4): 299.     CrossRef
  • Pleural Port-A-Cath for Symptomatic Refractory Hepatic Hydrothorax in Nontransplant Liver Patients
    Khaled Alshabani, Estefania Rivera, Alichia Paton, Juan Camilo Lara, Sebastian Fernandez-Bussy, Adnan Majid
    Annals of the American Thoracic Society.2024; 21(5): 823.     CrossRef
  • Medical thoracoscopy with talc pleurodesis for refractory hepatic hydrothorax: A case series of three successes
    Y. Rahim, R.V. Reddy, M. Naeem, G. Tsaknis
    Respiratory Medicine Case Reports.2024; 50: 102039.     CrossRef
  • ERS statement on benign pleural effusions in adults
    Anand Sundaralingam, Elzbieta M. Grabczak, Patrizia Burra, M. Inês Costa, Vineeth George, Eli Harriss, Ewa A. Jankowska, Julius P. Janssen, Georgia Karpathiou, Christian B. Laursen, Kornelija Maceviciute, Nick Maskell, Federico Mei, Blin Nagavci, Vasiliki
    European Respiratory Journal.2024; 64(6): 2302307.     CrossRef
  • Pulmonary complications of portal hypertension: The overlooked decompensation
    Rares Craciun, Tudor Mocan, Bogdan Procopet, Andrada Nemes, Cristian Tefas, Mihaela Sparchez, Lavinia-Patricia Mocan, Zeno Sparchez
    World Journal of Clinical Cases.2022; 10(17): 5531.     CrossRef
  • Modified indwelling pleural catheter versus silver nitrate pleurodesis for the management of malignant pleural effusion
    Mohammed F. Abdelghany, Khaled Essmat, Atef Farouk El-Karn, Sahar Farghly Youssif
    The Egyptian Journal of Chest Diseases and Tuberculosis.2022; 71(2): 248.     CrossRef
  • Hepatic Hydrothorax—An Independent Decompensating Event Associated with Long-Term Mortality in Patients with Cirrhosis
    Daniela Matei, Rares Craciun, Dana Crisan, Bogdan Procopet, Tudor Mocan, Sergiu Pasca, Roxana Zaharie, Bogdan Popovici, Zeno Sparchez
    Journal of Clinical Medicine.2021; 10(16): 3688.     CrossRef
  • Multidisciplinary Management of Hepatic Hydrothorax in 2020: An Evidence‐Based Review and Guidance
    Bubu A. Banini, Yahya Alwatari, Madeline Stovall, Nathan Ogden, Evgeni Gershman, Rachit D. Shah, Brian J. Strife, Samira Shojaee, Richard K. Sterling
    Hepatology.2020; 72(5): 1851.     CrossRef
  • Hepatic Hydrothorax: An Updated Review on a Challenging Disease
    Toufic Chaaban, Nadim Kanj, Imad Bou Akl
    Lung.2019; 197(4): 399.     CrossRef
  • Hepatic Hydrothorax
    Yong Lv, Guohong Han, Daiming Fan
    Annals of Hepatology.2018; 17(1): 33.     CrossRef
  • Efficacy and safety of intrapleural cisplatin versus silver nitrate in treatment of malignant pleural effusion
    Mohammad K. El Badrawy, Raed El-Metwally Ali, Asem A. Hewidy, Mohamed A. El-Layeh, Fatma M. F. Akl, Abdelhadi Shebl
    Egyptian Journal of Bronchology.2018; 12(1): 98.     CrossRef
  • Diagnóstico y manejo de los trasudados pleurales
    Lucía Ferreiro, José M. Porcel, Luis Valdés
    Archivos de Bronconeumología.2017; 53(11): 629.     CrossRef
  • Diagnosis and Management of Pleural Transudates
    Lucía Ferreiro, José M. Porcel, Luis Valdés
    Archivos de Bronconeumología (English Edition).2017; 53(11): 629.     CrossRef
  • Chemical pleurodesis by small bore catheter in hepatic hydrothorax: A feasibility study
    Asem A. Hewidy, Nasef Abdelsalam A. Rezk, Ahmed Abdel-Razik
    Egyptian Journal of Chest Diseases and Tuberculosis.2016; 65(1): 187.     CrossRef
  • Pigtail Catheter: A Less Invasive Option for Pleural Drainage in Egyptian Patients with Recurrent Hepatic Hydrothorax
    Mohamed Sharaf-Eldin, Adel Salah Bediwy, Abdelrahman Kobtan, Sherief Abd-Elsalam, Ferial El-Kalla, Loai Mansour, Walaa Elkhalawany, Mohamed Elhendawy, Samah Soliman
    Gastroenterology Research and Practice.2016; 2016: 1.     CrossRef
  • Effectiveness and Safety of Pleurodesis for Hepatic Hydrothorax: A Systematic Review and Meta-Analysis
    Feifei Hou, Xingshun Qi, Xiaozhong Guo
    Digestive Diseases and Sciences.2016; 61(11): 3321.     CrossRef
  • Hepatic hydrothorax: clinical review and update on consensus guidelines
    Rana Khazar Al-Zoubi, Mouhanna Abu Ghanimeh, Ashraf Gohar, Gary A. Salzman, Osama Yousef
    Hospital Practice.2016; 44(4): 213.     CrossRef
  • The management of benign non-infective pleural effusions
    Oliver J. Bintcliffe, Gary Y.C. Lee, Najib M. Rahman, Nick A. Maskell
    European Respiratory Review.2016; 25(141): 303.     CrossRef
  • Ultrasound-guided pleurodesis with doxycycline in patients with hepatic hydrothorax
    Ahmed M. Abd El Hafeez, Waleed F. Fathallah
    Egyptian Journal of Bronchology.2016; 10(1): 20.     CrossRef
  • Efficacy of nonsurgical tigecycline pleurodesis for the management of hepatic hydrothorax in patients with liver cirrhosis
    Nevin Yilmaz, Arife Zeybek, Benjamin Tharian, Ugur Eser Yilmaz
    Surgical Case Reports.2015;[Epub]     CrossRef
  • Three hepatocellular carcinoma patients with pleural effusion successfully treated by pleurodesis with a view to palliative medicine
    Junichi Senoo, Tetsuhiro Chiba, Tomoko Saito, Yoshihiko Ooka, Sadahisa Ogasawara, Hirotaka Koseki, Naoya Kanogawa, Eiichiro Suzuki, Akinobu Tawada, Osamu Yokosuka
    Kanzo.2015; 56(5): 213.     CrossRef
  • Management of refractory hepatic hydrothorax
    José M. Porcel
    Current Opinion in Pulmonary Medicine.2014; 20(4): 352.     CrossRef
  • Hepatic Hydrothorax
    John Paul Norvell, James R. Spivey
    Clinics in Liver Disease.2014; 18(2): 439.     CrossRef
  • Indwelling pleural catheters for benign pleural effusions
    O. J. Bintcliffe, D. T. Arnold, N. A. Maskell
    Current Respiratory Care Reports.2014; 3(2): 61.     CrossRef
  • Symptomatic hepatic hydrothorax successfully treated with transjugular intrahepatic portosystemic shunt (TIPS)–role of titration of portosystemic gradient reduction to avoid post‐TIPS encephalopathy
    T. L. Krishnamoorthy, M. Taneja, P. E. Chang
    Clinical Case Reports.2014; 2(3): 93.     CrossRef
  • Hidrotórax de causa hepática: análisis de 77 pacientes
    José M. Porcel, Estela Mas, Josep M. Reñé, Silvia Bielsa
    Medicina Clínica.2013; 141(11): 484.     CrossRef
  • Paradigms in the management of hepatic hydrothorax: past, present, and future
    Sachin Kumar, Shiv Kumar Sarin
    Hepatology International.2013; 7(1): 80.     CrossRef
  • Evidence-Based Review of the Management of Hepatic Hydrothorax
    Amita Singh, Abubakr Bajwa, Adil Shujaat
    Respiration.2013; 86(2): 155.     CrossRef
  • 11,412 View
  • 64 Download
  • Crossref